Clinical Trial Update: Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update describing a conditioning regimen of melphalan, fludarabine, and alemtuzumab followed by peripheral stem cell transplantation in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndrome
• Plasma Cell Neoplasm

Drugs mentioned

• Alemtuzumab (Alemtuzumab)
• Fludarabine (Fludarabine)
• Melphalan (Melphalan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2013-01-07